Inside USP: Global Harmonization Presents Opportunities and Challenges - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Inside USP: Global Harmonization Presents Opportunities and Challenges
To keep moving forward, the Pharmacopoeial Discussion Group needs industry participation.

Pharmaceutical Technology
Volume 36, Issue 1, pp. 67, 70

Challenges and industry participation

While the vision of harmonization is simple and straightforward, execution presents an array of challenges—some more easily addressed than others. Chief among these is differences in the regulatory and legal requirements of each country—which can make full harmonization difficult, or even impossible. Both JP and EP fall under ministerial bodies with a direct link to their respective regulatory agencies, while USP is an independent group separate from the FDA. To the degree possible with these constraints, PDG has managed to produce encouraging results. One approach is harmonization by attribute, which moves items forward where there is significant agreement on the main attributes (e.g., definition, assay, and identification testing), even if other portions of a standard are in dispute. This also allows PDG to avoid spending resources on topics where there are insurmountable differences, and focus on items where there is progress. Another challenge is the time required to bring harmonized monographs and chapters to public status. Although the seven-stage process will likely never be considered speedy, PDG is taking strides to move more efficiently.

Other challenges could be more easily addressed, such as by earlier and increased industry participation. Frequently, the potential for harmonization has not been realized by manufacturers and other stakeholders until late in the process. Moreover, comments to proposals published in Pharmacopeial Forum (PF), the online vehicle through which USP accepts feedback on standards, has often been received too late to be considered. Unlike the inherent challenges identified above, these are conquerable. USP has intensified educational and outreach activities to industry through free webinars, a dedicated webpage that centralizes and simplifies information http://( and activities. Moreover, USP began to offer PF free to all in January 2011, eliminating any barriers to accessing the journal (

Industry participation is crucial for harmonization to achieve its ultimate potential. Most vital is for manufacturers to take notice of harmonization proposals in PF at Stage 4 and submit comments to USP. If there are implementation problems with the methods proposed by PDG, USP must hear from industry at this stage. Given that manufacturers and users will be required to comply with the eventual standard, active engagement benefits all parties.

Hot topics and future work

PDG's workplan includes a variety of hot topics. Examples include the development of general chapters on elemental impurities, viscosity determination for excipients, and the strengthening of selected high-risk monographs to control for economically motivated adulteration. Also, PDG is looking at process and other potential improvements (e.g., accelerating harmonization). Harmonization is frequently cited as an essential activity but it desperately needs the full commitment of all parties if its promises and potential are to be realized.

Anthony DeStefano, PhD, is vice-president of general chapters, and Kevin Moore, PhD, is scientific liaison, both with the US Pharmacopeial Convention (USP).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here